We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+30.52%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.74B
AUM Growth
+$261M
(+11%)
Cap. Flow
-$140M
Cap. Flow
% of AUM
-5.1%
Top 10 Holdings %
Top 10 Hldgs %
32.74%
Holding
95
New
12
Increased
24
Reduced
31
Closed
21
Top Buys
| 1 |
Thermo Fisher Scientific
TMO
|
+$88.4M |
| 2 |
United Therapeutics
UTHR
|
+$54.7M |
| 3 |
CVS Health
CVS
|
+$52.7M |
| 4 |
Avantor
AVTR
|
+$43.5M |
| 5 |
AbbVie
ABBV
|
+$41.5M |
Top Sells
| 1 |
Cigna
CI
|
+$60.7M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$54.5M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
+$44.3M |
| 4 |
Zentalis Pharmaceuticals
ZNTL
|
+$42.1M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$38.5M |
Sector Composition
| 1 | Healthcare | 95.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arvinas
ARVN
$517M
| $123M | 4.48% |
2,985,117
+370,157
| +14% | +$8.65M |
|
2
Boston Scientific
BSX
$66.6B
| $109M | 3.98% |
1,890,000
-175,800
| -9% | -$9.38M |
|
|
3
CALL
Cigna
CI
$75B
| $105M | 3.82% |
+350,000
| New | +$102M |
|
|
4
Thermo Fisher Scientific
TMO
$200B
| $96.9M | 3.53% |
+182,600
| New | +$88.4M |
|
5
Acadia Healthcare
ACHC
$3.08B
| $89.9M | 3.28% |
1,156,692
+441,692
| +62% | +$32.7M |
|
6
Neurocrine Biosciences
NBIX
$17.3B
| $86.7M | 3.16% |
658,000
+5,900
| +0.9% | +$679K |
|
7
Syndax Pharmaceuticals
SNDX
$2.03B
| $85.4M | 3.11% |
3,950,000
+1,129,000
| +40% | +$17.4M |
|
8
Natera
NTRA
$38.9B
| $69.5M | 2.53% |
1,110,000
+211,000
| +23% | +$10.5M |
|
9
Danaher
DHR
$144B
| $67.1M | 2.45% |
290,000
+90,795
| +46% | +$19.3M |
|
10
Tenet Healthcare
THC
$17.1B
| $65.8M | 2.4% |
871,000
-92,800
| -10% | -$5.88M |
|
|
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $65.2M | 2.38% |
206,000
-80,700
| -28% | -$15.7M |
|
|
FUSN
12
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $62.5M | 2.28% |
6,500,328
+718,478
| +12% | +$3.49M |
|
|
13
Jazz Pharmaceuticals
JAZZ
$15.2B
| $60.2M | 2.19% |
489,119
-308,381
| -39% | -$38.5M |
|
14
Regeneron Pharmaceuticals
REGN
$71B
| $59.7M | 2.18% |
68,000
+10,000
| +17% | +$8.23M |
|
|
15
CVS Health
CVS
$136B
| $58.4M | 2.13% |
+740,000
| New | +$52.7M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $56.7M | 2.07% |
615,000
-136,600
| -18% | -$8.85M |
|
|
IMGN
17
DELISTED
Immunogen Inc
IMGN
| $54.2M | 1.98% |
1,829,215
-88,692
| -5% | -$1.77M |
|
18
IDEAYA Biosciences
IDYA
$3.47B
| $54.1M | 1.97% |
1,520,000
-624,971
| -29% | -$18.7M |
|
|
19
United Therapeutics
UTHR
$22.5B
| $52.2M | 1.9% |
+237,202
| New | +$54.7M |
|
20
Rocket Pharmaceuticals
RCKT
$378M
| $51.5M | 1.88% |
1,719,103
+131,674
| +8% | +$2.91M |
|
|
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $50.9M | 1.85% |
710,000
-91,100
| -11% | -$5.24M |
|
22
Eli Lilly
LLY
$1.04T
| $49.5M | 1.81% |
85,000
+10,000
| +13% | +$5.84M |
|
23
Biohaven
BHVN
$2.14B
| $49.1M | 1.79% |
1,148,308
-137,092
| -11% | -$4.26M |
|
|
24
Avantor
AVTR
$7.64B
| $48.4M | 1.77% |
+2,121,844
| New | +$43.5M |
|
25
Zoetis
ZTS
$32.4B
| $47.4M | 1.73% |
240,000
-22,100
| -8% | -$3.91M |
|
Similar funds
NM
PWAM
CM
LJAC
NI
MCM
TS
TW